Latest Biotech News

Eli Lilly is reshaping its obesity dependence narrative by acquiring non-GLP-1 assets, according to details tied to its Q1 2026 business updates. The company’s deal slate since January includes...

Vincentage Pharma said its oral GLP-1 agonist was associated with mean weight loss of 12.4% over one year and is preparing to pursue Eli Lilly’s orforglipron route with Chinese regulatory...

The FDA approved AstraZeneca’s baxdrostat for certain patients with hypertension, according to the company. Baxdrostat is intended to address elevated aldosterone pathways, giving physicians...

At ESTRO 2026, researchers presented approaches aimed at tailoring radiotherapy using circulating tumor DNA (ctDNA) and blood-based testing. The reported work describes a new blood test designed...

The Biotechnology Innovation Organization (BIO) submitted comments supporting the FDA’s proposed Plausible Mechanism Framework for individualized and disease-targeted therapies where traditional...

JPMorgan’s analysis shows biopharma dealmaking surged in Q1 2026, driven mainly by licensing and M&A even as venture capital stayed cautious toward early-stage risk. The report cited licensing...

Durabilityte unveiled a platform aimed at disrupting biologics production using implantable “cell factories”—cells engineered to secrete therapeutic proteins from inside the body. The concept...

Illumina’s Damon Hostin said clinical sequencing is positioned to enable more preemptive, preventative medicine, but insurance hurdles continue to limit widespread adoption. Hostin, head of market...

FDA has approved AstraZeneca’s baxdrostat for certain patients with hypertension, the company said Monday. The approval expands the regulatory footprint for baxdrostat and adds another option in...

Regeneron’s phase 3 melanoma program for its LAG-3 inhibitor missed its primary endpoint, leaving the company facing a second late-stage failure for a key program after a setback within the past...

Regenxbio shares fell sharply after investors reacted to guidance that the FDA may require a randomized controlled trial for its DMD gene therapy candidate RGX-202, despite positive pivotal phase...

Telitacicept, developed by RemeGen, showed a significant reduction in proteinuria in a prespecified interim analysis of a phase 3 trial in high-risk IgA nephropathy patients. In NEJM-published...

JPMorgan’s Q1 2026 biopharma licensing and venture report shows dealmaking momentum alongside tighter risk tolerance, with licensing value rising even as venture funding for early-stage companies...

Researchers presenting at ESTRO 2026 reported a new approach to guide treatment in advanced cancer using circulating tumor DNA (ctDNA) detected in blood plasma. The work positions ctDNA as a...

A study presented at ESTRO 2026 in Stockholm found that prostate cancer radiotherapy delivered in two larger doses over eight days was as safe and effective as a conventional five-fraction...

Researchers at ESTRO 2026 reported targeted stereotactic body radiotherapy (SBRT) data for oligometastatic breast cancer, indicating potential for extending control and progression-free survival...

An international clinical trial reported improved radiotherapy planning performance using AI for cervical and prostate cancer treatment, with investigators from University College London (UCL) and...

Biotech and pharma teams are increasingly turning to strategic outsourcing to capture more value from mature products as patent cliffs loom and internal resources face pressure. An analysis...

Regeneron’s LAG-3 inhibitor missed its primary endpoint in a phase 3 melanoma trial, failing to beat Merck’s Keytruda in the study readout. Analysts cited the result as the second late-stage...

Regenxbio’s RGX-202 generated positive pivotal phase 3 data for Duchenne muscular dystrophy, but investors reacted negatively after the FDA recommended the company run a randomized controlled...